Avoid common mistakes on your manuscript.
Correction to: Urolithiasis (2023) 51:80 https://doi.org/10.1007/s00240-023-01453-3
The original version of this article unfortunately contained a mistake. The copyright holder for this article was incorrectly given as
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply
but should have been
© The Author(s) 2023
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Goldfarb, D.S., Lieske, J.C., Groothoff, J. et al. Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Urolithiasis 51, 85 (2023). https://doi.org/10.1007/s00240-023-01455-1
Published:
DOI: https://doi.org/10.1007/s00240-023-01455-1